Balancing Reassurance and Vigilance: Real‐World Evidence in Post‐Marketing Drug Safety
Clinical Pharmacology & Therapeutics · 2026-06 · 119 (6) · 1401-1403
DOI: 10.1002/cpt.70302 ↗Kurz gefasst
Editorial in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 08.05.2026. Verfasst von Yow-Ming C Wang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver S…. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
- School of Pharmacy, University College London, London, UK.
- Department of Pharmacy, Great Ormond Street Hospital for Children, London, UK.
ORCID-Profile: Yow-Ming C Wang, Joseph F Standing
Zitieren
APA
Wang, Y. C., & Standing, J. F. (2026). Balancing Reassurance and Vigilance: Real‐World Evidence in Post‐Marketing Drug Safety. Clinical Pharmacology & Therapeutics, 119(6), 1401-1403. https://doi.org/10.1002/cpt.70302
Vancouver
Wang YC, Standing JF. Balancing Reassurance and Vigilance: Real‐World Evidence in Post‐Marketing Drug Safety. Clinical Pharmacology & Therapeutics. 2026;119(6):1401-1403. doi:10.1002/cpt.70302
BibTeX
@article{Wang2026,
author = {Wang, Yow-Ming C and Standing, Joseph F},
title = {Balancing Reassurance and Vigilance: Real‐World Evidence in Post‐Marketing Drug Safety},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
volume = {119},
number = {6},
pages = {1401--1403},
doi = {10.1002/cpt.70302}
}
EUVIMED